BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

ConferenceencaleretNeutral

AI Analysis

Summary

BridgeBio announced it will present additional evidence from the Phase 3 CALIBRATE trial of encaleret in ADH1 at the ASBMR 2026 Annual Meeting in Boston on October 9-12, 2026.

Clinical Trial Data

Phase

Phase 3

Importance:5/10

Sentiment:

0.20

Phase 3 trialconference presentationgenetic conditionADH1

Related Companies

$BBIO

Read the original article

Published by GlobeNewswire Clinical Studies on October 6, 2026 8:01 PM

Read Original